MIRA Pharmaceuticals CEO Erez Aminov, CEO joined Proactive’s Stephen Gunnion as the company started trading on the Nasdaq under the ticker symbol ‘MIRA’.
Aminov said MIRA is making groundbreaking advancements in the cannabis industry with the development of a synthetic marijuana analog that aims to revolutionize medicinal cannabis usage.
This new molecular entity, created using patented technology, offers the benefits of THC and CBD without their typical side effects, such as paranoia, anxiety, and impaired cognition. Clinical studies at John Hopkins Medical School revealed that this compound not only alleviates anxiety and chronic pain but also enhances cognition by 100% in animal studies.
MIRA’s synthetic THC is intended for medicinal use and is undergoing FDA approval. The pharmaceutical-grade version aims to provide a clean, safe, and effective option for patients, allowing them access to cannabis-based relief without the impurities and toxicity associated with plant-based marijuana.
Moreover, MIRA’s product stands out by being unscheduled, making it available to federal employees and veterans.
The company’s mission is to address unmet needs, such as anxiety and cognitive impairment in early-stage dementia patients, with minimal side effects.
MIRA Pharmaceuticals raised $8.9 million in the IPO, which will be primarily directed towards accelerating toxicology and clinical research to bring the revolutionary drug to market.
#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #MIRAPharmaceuticals #SyntheticTHC #CannabisInnovation #MedicinalCannabis #RevolutionaryMedicine #CBDAlternative #AnxietyRelief #ChronicPainSolution #CognitiveEnhancement #MedicalBreakthrough #FDAApproval #CleanCannabinoids #HealthcareInnovation #CannabisResearch #NeuropathicMedicine #UnmetMedicalNeeds #JohnHopkinsResearch #IPOSuccess #CannabisRevolution #VeteransHealth #FederalEmployees #SafeMedication #DementiaCare #CannabisScience #FutureOfMedicine #PharmaceuticalAdvancements
source
